On a Thursday morning in Denver, a British nephrologist will stand before the opening plenary of the American Society of Nephrology's Kidney Week and present the final efficacy analysis of ORIGIN 3, the trial testing whether atacicept can slow a kidney disease that quietly takes many patients toward dialysis or death. The company behind the drug, Vera Therapeutics, has already approved TRUTAKNA on an accelerated footing, resting on proof that it reduces protein leaking through damaged kidneys, while the deeper question of whether it protects kidney function over the long years remains open. Th
Vera Therapeutics to Present Final ORIGIN 3 Efficacy Data for TRUTAKNA at ASN Kidney Week 2026
IgA nephropathy can progress to kidney failure, dialysis, or death; at least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.
The announcement states no results; Denver is where they first become clear.
Mark
Why does this one plenary slot matter so much?
Mimi
It's the final efficacy analysis of ORIGIN 3, presented at the opening plenary on October 22. That's the meeting's most visible stage.
Mark
What's the drug approved for right now?
Mimi
Reducing proteinuria in adults with primary IgAN at risk of progression, under accelerated approval.
Luke
And that's the catch. Nobody has established that it slows kidney function decline over the long term. The announcement gives no results at all, only a schedule.
Mark
So what does the PIONEER work add?
Mimi
It widens the lens: interim data in adult IgAN and primary membranous nephropathy, plus a pediatric poster. Children aren't covered by the current label.
Luke
Interim is the operative word. Early results may not hold up later, as Vera's own risk language admits.
Mark
There's also a real-world poster.
Mimi
Yes, on rapid progression despite existing treatment in the US. It describes suboptimal disease control.
Luke
Worth noting that poster comes from a Vera author, and all five abstracts are company-sponsored. This is the company's own announcement, not independent review.
Mark
What's at stake for patients?
Mimi
At least half may reach kidney failure or death within 10 to 20 years, so a durable benefit would matter a great deal.
O Pulso
- The opening plenary of Kidney Week on October 22 becomes the stage where the final ORIGIN 3 efficacy results will be revealed to nephrologists worldwide.
- TRUTAKNA was approved on proteinuria reduction alone, leaving regulators and doctors waiting to learn whether it truly slows kidney decline.
- Vera Therapeutics is pressing forward with five abstracts, spanning adult and pediatric IgAN, membranous nephropathy, and real-world patient experience.
- Half of IgAN patients may face kidney failure or death within 10 to 20 years, so every data point carries heavy weight for patients and clinicians.
- Safety questions around infections and injection-site reactions will be weighed alongside efficacy as the results are scrutinized in Denver.
On a Thursday morning in Denver, a British nephrologist will stand before the opening plenary of the American Society of Nephrology's Kidney Week and present the final efficacy analysis of ORIGIN 3, the trial testing whether atacicept can slow a kidney disease that quietly takes many patients toward dialysis or death. The company behind the drug, Vera Therapeutics, has already approved TRUTAKNA on an accelerated footing, resting on proof that it reduces protein leaking through damaged kidneys, while the deeper question of whether it protects kidney function over the long years remains open. The data will become known only when the slides appear, so for now the meeting stands as a moment of waiting, where a rare disease's long story meets a single attempt to answer whether a promising therapy truly changes its course.
On Thursday, October 22, Jonathan Barratt, a professor of renal medicine at the University of Leicester, will step to a podium in Denver with seven minutes to present the final efficacy analysis of ORIGIN 3. His talk sits inside the opening plenary of the American Society of Nephrology's Kidney Week, a room full of kidney specialists waiting to hear whether atacicept can change the course of IgA nephropathy.
Vera Therapeutics, the company that sponsors the trial and sells the drug as TRUTAKNA, announced the schedule on October 2. The results will also appear on a poster that same day, and Vera has planned five abstracts in total, including interim PIONEER data in adult IgAN and primary membranous nephropathy, pediatric IgAN work, and real-world evidence on patients who progress despite treatment.
TRUTAKNA is given at home as a once-weekly autoinjector and reduces proteinuria in adults at risk of progression. Its approval is accelerated, which means it has not yet been shown whether it slows long-term kidney decline. That question is why the ORIGIN 3 data matter so much.
IgAN is a progressive disease that often strikes between ages 30 and 40, and at least half of patients may face kidney failure or death within two decades. The labeling notes infections and injection-site reactions, and the announcement itself reveals no results, so the answer will arrive only when the presentation begins.
On Thursday, October 22, at 9:05 in the morning Mountain time, Jonathan Barratt will have seven minutes at the podium in the Bluebird Ballroom of the Denver convention center. Barratt, a PhD and the Mayer Professor of Renal Medicine at the University of Leicester, is scheduled to present the final efficacy analysis of ORIGIN 3, the trial of atacicept in IgA nephropathy. The talk falls inside the opening plenary of the American Society of Nephrology's Kidney Week, which runs October 22 to 25. The plenary itself runs from 8:00 to 9:30 AM.
Vera Therapeutics, the Brisbane, California company that sponsors the trial and sells the drug under the name TRUTAKNA (atacicept-vymj), announced the schedule on October 2. The ORIGIN 3 results will also appear as a late-breaking research poster the same day, on board TH-PO1257. The abstract number for the oral talk is TH-OR109.
ORIGIN 3 is one of five Vera-sponsored abstracts at the meeting. On Saturday, October 24, Richard Lafayette, director of the Glomerular Disease Center at Stanford University Medical Center, will present interim results from the adult IgAN and primary membranous nephropathy cohorts of PIONEER. That is a Phase 2 basket trial of atacicept across several glomerular diseases. His talk is set for 5:30 to 5:40 PM in Four Seasons Ballroom 2, within a late-breaking session on pediatrics, genetics, and glomerular disease.
Three more posters will go up in the Exhibit Hall on Saturday morning, from 10:00 AM to noon. Howard Trachtman of the University of Michigan will describe how PIONEER is extending evaluation of atacicept to pediatric IgAN patients. Damemarie Paul of Vera will present real-world evidence titled "Rapid Progression in IgAN Despite Treatment," which examines suboptimal disease control in the United States. Navdeep Tangri of the University of Manitoba will present Aurora, a multi-site clinical implementation network for IgA nephropathy.
TRUTAKNA is a BAFF and APRIL inhibitor, a fusion protein that binds the two cytokines that activate B cells and drive IgAN. It is given at home as a 150 mg, 1 ml once-weekly autoinjector. It is indicated to reduce proteinuria in adults with primary IgAN who are at risk of disease progression. Vera describes it as the first approved therapy targeting both BAFF and APRIL, and its prescribing information is dated July 2026.
The approval is an accelerated one, based on reduction of proteinuria. It has not been established whether the drug slows long-term kidney function decline, and continued approval may depend on a confirmatory trial showing clinical benefit. That is the context in which the final ORIGIN 3 analysis will be read.
The disease is the reason the stakes are high. IgAN is a progressive, immune-mediated kidney disease, diagnosed in roughly 2.5 adults per 100,000 worldwide each year, most often between ages 30 and 40. It can cause irreversible kidney damage and may require dialysis or transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.
The labeling lists risks. Infections were reported in 32% of TRUTAKNA patients versus 28% on placebo, and local administration reactions in 30% versus 5%. Live vaccines are not recommended within 30 days before or during treatment, and pediatric safety and effectiveness have not been established. The announcement does not state any ORIGIN 3 results, so what the data show will first become clear in Denver on October 22.
Citações Notáveis
The accelerated approval rests on proteinuria reduction; long-term slowing of kidney function decline has not been established.— TRUTAKNA indication statement, Vera Therapeutics
Quer a matéria completa?
Leia o original em The Manila Times ↗
Economy & Finance